<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        4-470-12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2012
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        PRIVIGEN 10% SOLUTION FOR INFUSION
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        HUMAN IMMUNOGLOBULIN G
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        10
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        %
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intravenous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        25
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        1120.70
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="CSL BEHRING" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            CSL BEHRING
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            CSL BEHRING
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J06BA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Privigen belongs to the class of medicines called human normal immunoglobulins. Immunoglobulins are<br />30 also known as antibodies and are blood proteins that help your body to fight infections.</p><p>Privigen is used for the treatment of adults and children (0-18 years) in the following situations:<br /><br />&nbsp;to raise abnormally low immunoglobulin levels in your blood to normal levels (replacement<br />&nbsp;therapy). There are five groups:<br />&nbsp;1. Patients who are born with a reduced ability or inability to produce immunoglobulins<br />&nbsp;(primary immunodeficiencies (PID)).<br />&nbsp;2. Patients with blood cancer (chronic lymphocytic leukaemia) who have low immunoglobulin<br />&nbsp;levels in the blood (hypogammaglobulinaemia) and develop recurrent infections and for<br />&nbsp;whom preventative antibiotics have failed.<br />&nbsp;3. Patients with bone marrow cancer (multiple myeloma) who have low immunoglobulin levels<br />&nbsp;in the blood and develop recurrent infections, if no immune response is obtained after<br />&nbsp;vaccination against certain bacteria (pneumococci).<br />&nbsp;4. Patients who have low immunoglobulin levels in the blood after transplantation of stem cells<br />&nbsp;from another person.<br />54 5. Patients with inborn AIDS (Acquired Immunodeficiency Syndrome) and recurrent infections.<br /><br />&nbsp;B) to treat certain inflammatory disorders (immunomodulation). There are five groups:<br />&nbsp;1. Patients who do not have enough blood platelets (primary immune thrombocytopenia (ITP)<br />&nbsp;and who are at high risk of bleeding or will have surgery in the near future.<br />&nbsp;2. Patients with Guillain-Barr&eacute; syndrome. This is an acute disease that is characterised by<br />&nbsp;inflammation of the peripheral nerves that causes severe muscle weakness mainly in the legs<br />&nbsp;and upper limbs.<br />&nbsp;3. Patients with Kawasaki disease. This is an acute disease that primarily affects young children.<br />&nbsp;It is characterised by inflammation of blood vessels throughout the body.<br />&nbsp;4. Patients with chronic inflammatory demyelinating polyneuropathy (CIDP). This is a chronic<br />&nbsp;disease that is characterised by inflammation of the peripheral nerves that causes muscle<br />&nbsp;weakness and/or numbness mainly in the legs and upper limbs.<br />&nbsp;5. Patients with multifocal motor neuropathy, Myasthenia Gravis exacerbations, Lambert-Eaton</p><p>&nbsp;Myasthenic 68 Syndrome and Stiff Person Syndrome.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do NOT inject Privigen:<br />&bull; if you are allergic to human immunoglobulins or to proline.<br />&nbsp;if you have developed antibodies against immunoglobulins of the type IgA in your blood.</p><p>77 Warnings and precautions<br />78 For your personal safety, treatment with Privigen will take place under the supervision of your doctor or<br />79 healthcare professional. You will usually be observed during the whole infusion and for at least 20 minutes<br />80 thereafter. In certain circumstances, special precautions may be necessary. Examples of such circumstances<br />81 are:<br />82 &bull; you are receiving Privigen at a high infusion rate or<br />83 &bull; you are receiving Privigen for the first time or after a long break in treatment (e.g. several months).<br />84 In these cases you will be closely observed during the whole infusion and for at least 1 hour afterwards.<br />85<br />86 In all patients, IVIg administration requires adequate hydration prior to the initiation of the infusion.<br />87<br />88 Tell your doctor or healthcare professional immediately if you notice the following reactions during the<br />89 infusion of Privigen. He or she will decide whether to decrease the infusion rate or to stop the infusion<br />90 completely:<br />91<br />92 Hypersensitivity / Anaphylaxis<br />93 You may be allergic (hypersensitive) to immunoglobulins without knowing it.<br />94 However, true allergic reactions are rare. They may occur even if you have previously received human<br />95 immunoglobulins and had tolerated them well. It may happen particularly if you have developed antibodies<br />96 against immunoglobulins of the type IgA. In these rare cases allergic reactions such as a sudden fall in<br />97 blood pressure or shock may occur (see also section 4).<br />98<br />99 Haemolysis</p><p>You receive this medicine in high doses either on 1 day or over 100 several days and you have a blood group<br />101 A, B or AB and/or you have an underlying inflammatory condition. In these circumstances, it has been<br />102 commonly reported that immunoglobulins increase the risk of breakdown of red blood cells (haemolysis)<br />103 (see also section 4).<br />104<br />105 Aseptic Meningitis Syndrome (AMS)<br />106 Tell your doctor if you experience the following signs and symptoms: severe headache, neck stiffness,<br />107 drowsiness, fever, photophobia, nausea, and vomiting after receiving Privigen. These symptoms might<br />108 indicate aseptic meningitis, a temporary and reversible non-infectious inflammation of the protective<br />109 membranes surrounding the brain and spinal cord. Your doctor will decide if further tests are necessary and<br />110 whether Privigen infusion should be continued.<br />111<br />112 Blood clots (thromboembolism)<br />113 You are overweight, are elderly (over 65 years of age), have diabetes, have been bedridden for a long time,<br />114 have high blood pressure, have low blood volume (hypovolaemia), have problems with your blood vessels<br />115 (vascular diseases), have an increased tendency for blood clotting (thrombophilia or thrombotic episodes)<br />116 or have a disease or a condition which causes your blood to thicken (hyperviscous blood). In these<br />117 circumstances, immunoglobulins may increase the risk of heart attack (cardiac infarction), stroke, blood<br />118 clots in the lung (lung embolism), or blockage of a blood vessel in the leg, although only very rarely (see<br />119 also section 4).<br />120<br />121 Acute renal failure<br />122 You have or had previously problems with your kidneys or take medicinal products that may harm your<br />123 kidneys (nephrotoxic medicinal products). In these circumstances, immunoglobulins may increase the risk<br />124 of serious rapid loss of kidney function (acute renal failure) although only very rarely. Loss of kidney<br />125 function with fatal outcome has occurred in isolated haemolysis-related cases (see also section 4).<br />126<br />127 Transfusion-related acute lung injury (TRALI)<br />128 In very rare cases transfusion-related acute lung injury (TRALI) can occur after receiving<br />129 immunoglobulins including Privigen. This will lead to non-heart related accumulation of fluid in the air<br />130 spaces of the lungs (non-cardiogenic pulmonary oedema). You will recognize TRALI by severe difficulty<br />131 in breathing (respiratory distress), abnormally low level of oxygen in the blood (hypoxemia), normal heart<br />132 function (left ventricular function) and increased body temperature (fever). Symptoms typically appear<br />133 within 1 to 6 hours after receiving treatment (see also section 4).</p><p>Tell your doctor or healthcare professional prior to treatment with Privigen 135 if any of the circumstances<br />136 listed below applies to you:</p><p>139 Diabetes<br />140 You are diabetic. Although Privigen does not contain sugar, it may be diluted with a special sugar solution<br />141 (5% glucose), which could affect your blood sugar level.<br />142<br />143 Sodium content<br />144 You are on sodium diet. Privigen is essentially sodium-free.<br />145<br />146 Blood tests<br />147 You plan to have certain blood tests. After receiving Privigen, the results of certain blood tests (serological<br />148 tests) may be impaired for a certain time.<br />149<br />150 Speak with your doctor or healthcare professional prior to treatment with Privigen about pathogen<br />151 safety:<br />152<br />153 Pathogen safety<br />154 Privigen is made from human blood plasma (this is the liquid part of the blood). When medicines are made<br />155 from human blood or plasma, certain measures are put in place to prevent infections being passed on to<br />156 patients. These include:<br />157 &bull; careful selection of blood and plasma donors to make sure those at risk of carrying infections are<br />158 excluded,<br />159 &bull; the testing of each donation and pools of plasma for signs of virus/infections,<br />160 &bull; the inclusion of steps in the processing of the blood or plasma that can inactivate or remove<br />161 viruses.<br />162 Despite these measures, when medicines prepared from human blood or plasma are administered, the<br />163 possibility of passing on infection cannot be totally excluded. This also applies to any unknown or<br />164 emerging viruses and other types of infections.</p><p>The measures taken are considered effective for enveloped viruses such as human 166 immunodeficiency virus<br />167 (HIV), hepatitis B virus and hepatitis C virus, and for the non-enveloped hepatitis A virus and parvovirus<br />168 B19.<br />169<br />170 Immunoglobulins have not been associated with hepatitis A or parvovirus B19 infections, possibly because<br />171 antibodies against these infections, which are contained in the product, are protective.<br />172<br />173 Other medicines and Privigen<br />174 Tell your doctor or healthcare professional if you are using, have recently used or might use any other<br />175 medicines.<br />176<br />177 Tell your vaccinating doctor prior to a vaccination about your treatment with Privigen:<br />178<br />179 Live attenuated virus vaccines<br />180 After receiving Privigen, the efficacy of certain vaccinations may be impaired. Affected are vaccinations<br />181 with live attenuated virus vaccines such as vaccinations against measles, mumps, rubella and varicella.<br />182 Such vaccinations should be postponed for at least 3 months after the last infusion of Privigen. In the case<br />183 of measles vaccinations the impairment may persist for up to 1 year. Therefore, your vaccinating doctor<br />184 should check the effectiveness of the measles vaccination.<br />185<br />186 Pregnancy, breastfeeding and fertility<br />187 Tell your doctor or healthcare professional if you are pregnant, plan to become pregnant or are breast188<br />feeding.<br />189 Your doctor will decide whether you can receive Privigen during your pregnancy or while you are breast190<br />feeding.<br />191 Medicines containing antibodies have been used in pregnant or breast-feeding women. Long-term<br />192 experience has shown that no harmful effects during the course of the pregnancy or to the newborn are to<br />193 be expected.<br />194 If you are breast-feeding and you receive Privigen this medicine will also be found in the breast milk.<br />195 Thus, also your baby may receive the protective antibodies.<br />196<br />197 Driving and using machines</p><p>Patients may experience effects, such as dizziness or nausea, during treatment with 198 Privigen that might<br />199 affect the ability to drive and use machines. If this happens, you should not drive or use machines until<br />200 these effects have disappeared.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>205 Always use this medicine exactly as your doctor has told you. Check with your doctor if you are not sure.<br />206<br />207 Dosage<br />208 Your doctor will calculate the correct dose for you taking into account your weight, the specific<br />209 circumstances listed under section 2 and response to treatment. The dose calculation for children and<br />210 young patients is not different from that for adults.<br />211 Your healthcare professional may adjust the dose based on your response to the treatment.<br />212<br />213 If you think you should receive Privigen more or less frequently, please speak to your doctor.<br />214 If you think you have missed a dose, speak to your doctor as soon as possible.<br />215<br />216 Method and route of administration<br />217 Privigen is intended solely for the infusion into a vein (intravenous infusion). It is usually administered by<br />218 your doctor or healthcare professional.<br />219<br />220 Infusion rate<br />221 At the beginning of the infusion you will receive Privigen at a slow infusion rate. If you tolerate this well,<br />222 your doctor can gradually increase the infusion rate.<br />223 If you are a patients at a risk, as described in section 2, your doctor will administer Privigen at the<br />224 minimum dose and infusion rate practicable.<br />225<br />226 Other instructions for use<br />227 &bull; Privigen is a ready-to-use solution (see section 5).<br />228 &bull; Administer solution which is at room (25 &deg;C) or body temperature.<br />229 &bull; Once a vial has been opened, use the solution immediately.<br />230 &bull; Use aseptic technique when preparing and administering Privigen.</p><p>Record the following data 231 in your treatment diary:<br />232  the date of administration,<br />233  the batch number of the medicine, and<br />234  the injected volume, flow rate, the number and location of injection sites.<br />235<br />236 If you have any further questions on the use of this medicine, please ask your doctor or healthcare<br />237 professional.<br />238<br />239 If you use more Privigen than you should<br />240 If you think you have had too much Privigen, speak to your doctor as soon as possible.<br />241 Overdose is very unlikely to occur because Privigen is usually administered under medical supervision. If,<br />242 in spite of this, you receive more Privigen than you should, your blood may become too thick<br />243 (hyperviscous). This may happen particularly if you are a patient at risk, for example if you are elderly or if<br />244 you suffer from a heart or kidney disease. Tell your doctor if you are known to have medical problems.</p><p>246 If you forget to use Privigen<br />247 If you think you have missed a dose, speak to your doctor as soon as possible.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; stiff neck together with one or more of the following symptoms: 265 fever, nausea, vomiting,<br />266 headache, abnormal sensitivity to light, mental disturbances<br />267 Tell your doctor or healthcare professional immediately if you have any of the above symptoms<br />268 that might indicate temporary non-infectious meningitis (reversible aseptic meningitis).<br />269<br />270 &bull; transient skin reactions<br />271<br />272 &bull; transient decrease in red blood cells (reversible haemolytic anaemia/haemolysis)<br />273 &bull; anaemia, leukopenia, anisocytosis (including microcytosis).<br />274 Tell your doctor or healthcare professional immediately if you notice such signs during the<br />275 infusion of Privigen. He or she will decide whether to decrease the infusion rate or to stop the<br />276 infusion completely.<br />277<br />278 &bull; increase in blood creatinine level<br />279 &bull; proteinuria<br />280 &bull; acute renal failure<br />281 Tell your doctor or healthcare professional immediately if you notice such signs during the<br />282 infusion of Privigen. He or she will decide whether to decrease the infusion rate or to stop the<br />283 infusion completely.<br />284<br />285 &bull; chest pain, chest discomfort, painful respiration due to transfusion related lung injury (TRALI)<br />286 &bull; formation of blood clots which may be carried off in the blood circulation (thromboembolic<br />287 reactions) and which may result e.g. in myocardial infarction (e.g. when you have sudden chest<br />288 pain or shortness of breath), stroke (e.g. when you have a sudden onset of muscle weakness, have<br />289 loss of sensation and/or balance, decreased alertness or difficulty in speaking), blood clots in the<br />290 arteries of the lungs (e.g. when you have chest pain, difficulty in breathing or are coughing up<br />291 blood), deep vein thrombosis (e.g. when you have redness, feel warmth, pain, tenderness, or have a<br />292 swelling of one or both legs)<br />293 Tell your doctor or healthcare professional immediately if you have any of the above symptoms.<br />294 Anyone experiencing such symptoms should immediately be transported to a hospital emergency<br />295 room for evaluation and treatment.</p><p>Side effects observed in controlled clinical studies presented 298 in order of decreasing frequency<br />299<br />300 Very Common (may occur with more than 1 in 10 patients):<br />301 headache (including sinus headache, migraine, head discomfort, tension headache), upset stomach<br />302 (nausea), pain (including back pain, pain in extremity, joints and bones (arthralgia), neck pain, facial pain,<br />303 fever (including chills), flu-like illness (including runny nose (nasopharyngitis), sore throat<br />304 (pharyngolaryngeal pain), blisters in mouth and throat (oropharyngeal blistering), throat tightness).</p><p>306 Common (may occur with up to 1 in 10 patients):<br />307 temporary lowering of red blood cell count (anaemia), breakdown of red blood cells (haemolysis including<br />308 haemolytic anaemia), decreased number of white blood cells (leukopenia), hypersensitivity, dizziness<br />309 (including vertigo), high blood pressure (hypertension), flushing (including hot flush, increase of blood<br />310 flow to different tissues in the body (hyperaemia)), low or decreased blood pressure (hypotension),<br />311 breathlessness (dyspnoea, including chest pain, chest discomfort, painful breathing), vomiting, loose stools<br />312 (diarrhea), abdomen pain, changes in the routine laboratory tests to liver functions (hyperbilirubinaemia),<br />313 skin disorder (including rash, itching (pruritus), hives (urticaria), maculopapular rash, redness of the skin<br />314 (erythema), peeling of the skin (skin exfoliation)), pain in the muscles (myalgia, including muscle cramps<br />315 and rigidity, and musculoskeletal pain), tiredness (fatigue), physical weakness (asthenia, including<br />316 muscular weakness), changes in the routine laboratory tests of blood (decreased haemoglobin including<br />317 decreased red blood cell count and decreased haematocrit, Coombs&rsquo; (direct) test positive for blood counts,<br />318 increased alanine aminotransferase, increased aspartate aminotransferase, increased blood lactate<br />319 dehydrogenase).<br />320<br />321 Uncommon (may occur with up to 1 in 100 patients):<br />322 temporary non-infectious meningitis (aseptic meningitis), irregularity of red blood cell shape (anisocytosis<br />323 including microcytosis (microscopic finding)), presence of high platelet counts in the blood<br />324 (thrombocytosis), sleepiness, shiver (tremor), palpitations, tachycardia, thromboembolic events, lack of<br />325 blood supply to the lower extremities causing e.g. pain when walking (vasculitis including peripheral<br />326 vascular disorder), presence of an excess of serum proteins in the urine (proteinuria including increased<br />327 blood creatinine), injection site pain.</p><p>329 Reporting of side effects</p><p>If you get any side effects, talk to your your doctor or healthcare professional. 330 This includes any possible<br />331 side effects not listed in this leaflet. By reporting side effects you can help provide more information on the<br />332 safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>337 &bull; Do not use this medicine after the expiry date (EXP) which is stated on the outer carton and the<br />338 vial label after EXP. The expiry date refers to the last day of that month.<br />339 &bull; Privigen should be administered as soon as possible after opening the vial as the solution contains<br />340 no preservative.<br />341 &bull; Do not store above 25 C. Do not freeze.<br />342 &bull; Do not use solutions that have been frozen.<br />343 &bull; Do not shake.<br />344 &bull; Keep this medicine out of the sight and reach of children.<br />345 &bull; Keep the vial in the outer carton in order to protect from light.<br />346 &bull; Do not use this medicine if you notice that the solution is cloudy or has particles floating within the<br />347 solution.<br />348 &bull; Do not throw away any medicines via wastewater or household waste. Ask your doctor or<br />349 healthcare professional how to throw away medicines you no longer use. These measures will help<br />350 protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>356 &bull; The active substance is human normal immunoglobulin (antibodies of the type immunoglobulin G<br />357 (IgG)). Privigen contains 100 mg/ml (10%) human protein of which at least 98% is IgG.<br />358 The approximate percentage of IgG subclasses is as follows:<br />359 IgG1 ..................... 67.8%<br />360 IgG2 ..................... 28.7%<br />361 IgG3 ....................... 2.3%<br />362 IgG4 ....................... 1.2%</p><p>This medicine contains trace amounts of immunoglobulin 363 of the type A (IgA) (not more than 25<br />364 micrograms/ml).<br />365 &bull; The other ingredients (excipients) are the amino acid proline and water for injections.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                8 Privigen is presented as a solution for infusion.
369 The solution is clear or slightly opalescent and colourless to pale-yellow.
370
371 Pack sizes
372 Packs of 1 vial (2.5 g/25 ml, 5 g/50 ml, 10 g/100 ml), or 3 vials (10 g/100 ml).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>376 CSL Behring AG<br />377 Bern, Switzerland<br />378 For any information about this product, please contact the local representative of the Marketing<br />379 Authorisation Holder:<br />380 FAHAD AL-HADAYAN<br />381 Office number 1, Floor number 7, Elnemer bulding, Olaya, Riyadh, Kingdom of Saudi Arabia<br />382 Tel: +966590800022<br />383 fahad.alhadayan@cslbehring.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                10/2017
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>NA Hospital item</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>NA Hospital item</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>NA Hospital item</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>NA Hospital item</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>NA Hospital item</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>NA Hospital item</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>NA Hospital item</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>NA Hospital item</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            NA Hospital item
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Privigen®
Human normal immunoglobulin
Solution for infusion (10%)
For intravenous use only
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                a. Active substance
Human immunoglobulin for intravenous use (IVIg)*.
Human plasma protein containing at least 98% immunoglobulin G (IgG).
Distribution of the IgG subclasses (average values): IgG1 67.8%, IgG2 28.7%, IgG3 2.3%,
IgG4 1.2%.
The maximum IgA content is 25 micrograms/ml.
*Produced from the plasma of human donors.
b. Excipients
L-proline, water for injections.
Privigen contains trace amounts of sodium (≤ 1 mmol/l).
Privigen contains no preservatives.
Privigen contains no carbohydrate stabiliser (e.g. sucrose, maltose).
Pharmacotherapeutic group
Immune sera and immunoglobulins: immunoglobulins, normal human, for intravascular
administration.
ATC code:
J06BA02
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for intravenous infusion.
1 ml of solution contains: 100 mg human plasma protein with an IgG content of at least 98%
(10% solution).
The solution is clear to slightly opalescent and colourless to pale yellow. Privigen is isotonic,
with an osmolality of 320 mOsmol/kg.
The pH value of the ready-to-use solution is 4.6 to 5.0 [4.8].
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Replacement therapy in<br />&bull; Primary immunodeficiency syndromes (PID) such as:<br />&ndash; congenital agammaglobulinaemia and hypogammaglobulinaemia<br />&ndash; common variable immunodeficiency<br />&ndash; severe combined immunodeficiency<br />&ndash; Wiskott-Aldrich syndrome<br />&bull; Myeloma or chronic lymphocytic leukaemia with severe secondary<br />hypogammaglobulinaemia and recurrent infections<br />&bull; Children with congenital AIDS and recurrent infections<br />Immunomodulation<br />&bull; Immune thrombocytopenic purpura (ITP) in children or adults at high risk of bleeding<br />or prior to surgical interventions to correct the platelet count<br />&bull; Guillain-Barr&eacute; syndrome<br />&bull; Kawasaki disease<br />&bull; Chronic inflammatory demyelinating polyneuropathy (CIDP)<br />Allogeneic bone marrow transplantation</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>&nbsp;</p><p>The dosage and dosage regimen is dependent on the indication. In replacement therapy the<br />dosage may need to be individualised for each patient depending on the pharmacokinetic and<br />clinical response. The following dosage regimens are given as a guideline.<br />Replacement therapy in primary immunodeficiency syndromes<br />The dosage regimen should achieve a trough IgG level (measured before the next infusion) of<br />at least 5 to 6 g/l. Three to 6 months are required after the initiation of therapy for<br />equilibration to occur. The recommended starting dose is 0.4 to 0.8 g/kg body weight (bw)<br />followed by at least 0.2 g/kg bw every 3 to 4 weeks.<br />The dose required to achieve a trough level of 5 to 6 g/l is of the order of 0.2 to<br />0.8 g/kg bw/month. The dosage interval when steady state has been reached varies from 3 to<br />4 weeks. Trough levels should be measured in order to adjust the dose and dosage interval.<br />Replacement therapy in myelomas or chronic lymphocytic leukaemia with severe secondary<br />hypogammaglobulinaemia and recurrent infections; replacement therapy in children with<br />congenital AIDS and recurrent infections<br />The recommended dosage is 0.2 to 0.4 g/kg bw every 3 to 4 weeks.</p><p>Immune thrombocytopenic purpura<br />For the treatment of an acute episode, 0.8 to 1 g/kg bw on day one, which may be repeated<br />once within 3 days, or 0.4 g/kg bw daily for 2 to 5 days. The treatment can be repeated if<br />relapse occurs (see also section &ldquo;Properties/Effects&rdquo;).</p><p>Guillain-Barr&eacute; syndrome<br />0.4 g/kg bw/day over 5 days. Experience in children is limited.<br />Kawasaki disease<br />1.6 to 2.0 g/kg bw should be administered in divided doses over 2 to 5 days or 2.0 g/kg bw as<br />a single dose. Patients should receive concomitant treatment with acetylsalicylic acid.<br />Chronic inflammatory demyelinating polyneuropathy (CIDP)<br />The recommended starting dose is 2 g/kg bw divided over 2 to 5 consecutive days followed<br />by maintenance doses of 1 g/kg bw given on one day or divided over 2 consecutive days<br />every 3 weeks.<br />The long-term therapy over 25 weeks depends on the patient`s response to the maintenance<br />therapy. The lowest effective maintenance dose and the dosage regimen are to adjust<br />according to the individual course of the disease.<br />Allogeneic bone marrow transplantation<br />Human immunoglobulin therapy can be used as part of the conditioning regimen and after<br />transplantation. To treat infections and prevent graft-versus-host disease, the dosage should be<br />individually adjusted.<br />The starting dosage is usually 0.5 g/kg bw/week, commencing seven days before the<br />transplant. The treatment is continued for up to 3 months after the transplant. If the lack of<br />antibody production persists, a dosage of 0.5 g/kg bw/month is recommended until IgG<br />antibody levels return to normal.</p><p>The dosages recommendations are summarised in the following table:</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="width:206px">Indications</td><td style="width:111px">Dose</td><td style="width:181px">Intervals between injections</td></tr><tr><td style="width:206px"><p>Replacement therapy in<br />primary immunodeficiency syndromes</p><p>secondary immunodeficiency syndromes</p><p>children with congenital HIV infection<br />and recurrent infections</p></td><td style="width:111px"><p>starting dose:<br />0.4-0.8 g/kg bw<br />thereafter:</p><p>0.2-0.8 g/kg bw</p><p>0.2-0.4 g/kg bw</p><p>0.2-0.4 g/kg bw</p><p>&nbsp;</p></td><td style="width:181px"><p>every 3-4 weeks to obtain IgG<br />trough levels of at least 5-6 g/l</p><p>every 3-4 weeks to obtain IgG<br />trough levels of at least 5-6 g/l</p><p>every 3-4 weeks</p></td></tr><tr><td style="width:206px"><p>Immunomodulation<br />Immune thrombocytopenic purpura</p><p>Guillain-Barr&eacute; syndrome<br />Kawasaki disease</p><p>Chronic inflammatory demyelinating<br />polyneuropathy (CIDP)</p></td><td style="width:111px"><p>0.8-1 g/kg bw</p><p>or<br />0.4 g/kg bw/day</p><p>0.4 g/kg bw/day</p><p>1.6-2 g/kg bw</p><p>or<br />2 g/kg bw</p><p>starting dose:<br />2 g/kg bw</p><p>maintenance dose:<br />1 g/kg bw</p></td><td style="width:181px"><p>on the first day; the therapy may<br />be repeated once within 3 days</p><p>over 2-5 days</p><p>over 5 days</p><p>divided into several doses given<br />over 2-5 days in conjunction with<br />acetylsalicylic acid</p><p>as a single dose in conjunction<br />with acetylsalicylic acid</p><p>in divided doses over 2-5 days</p><p>every 3 weeks over 1-2 days</p><p>&nbsp;</p></td></tr><tr><td style="width:206px"><p>Allogeneic bone marrow transplantation<br />&ndash; treatment of infections and prevention<br />of graft-versus-host disease</p><p>&ndash; persistent lack of antibody production</p></td><td style="width:111px"><p>0.5 g/kg bw</p><p>0.5 g/kg bw</p></td><td style="width:181px"><p>weekly, from day 7 before<br />up to 3 months after the<br />transplant</p><p>monthly, until antibody levels<br />return to normal</p></td></tr></tbody></table><p>bw = body weight</p><p>Use of the product in paediatric population<br />In the phase III pivotal study on patients with primary immunodeficiency diseases (n = 80),<br />19 patients between 3 and 11 years of age and 15 patients from 12 up to and including 18<br />years of age were treated. In an extension study of patients with primary immunodeficiency<br />diseases (n = 55), 13 patients between 3 and 11 years of age and 11 between 12 and including<br />18 years of age were treated</p><p>Method of administration<br />Privigen should be infused intravenously.<br />Rate of infusion<br />The product should initially be infused at a rate of 0.3 ml/kg bw/hr (for approximately 30<br />min). If well tolerated, the infusion rate can be gradually increased to 4.8 ml/kg bw/hr. In<br />patients with immunodeficiency syndrome who have tolerated substitution treatment with<br />Privigen well, the infusion rate may be gradually increased to a maximal value of 7.2 ml/kg<br />bw/hr.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or the excipient (see section “Composition”).
Hypersensitivity to human immunoglobulins, especially in patients with IgA deficiency where
the patient has anti-IgA antibodies.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Certain severe adverse reactions may be related to the rate of infusion. The recommended<br />infusion rate given under section &ldquo;Dosage/Administration: Method of administration&rdquo; must be<br />closely followed. Patients must be closely monitored and carefully observed for any<br />symptoms throughout the infusion period and thereafter.<br />Certain adverse reactions may occur more frequently:<br />&ndash; in case of high rate of infusion,<br />&ndash; in patients with hypogammaglobulinaemia or agammaglobulinaemia, with or without<br />IgA deficiency,<br />&ndash; in patients who receive human normal immunoglobulin for the first time or, in rare<br />cases, when the human normal immunoglobulin product is switched or when there has<br />been a long interval since the previous infusion.<br />Potential complications can often be avoided by ensuring that patients:<br />&ndash; are not sensitive to human normal immunoglobulin by initially infusing the product<br />slowly (0.3 ml/kg bw/hr);<br />&ndash; are carefully monitored for any symptoms throughout the infusion period. In particular,<br />patients, naive to human normal immunoglobulin, switched from an alternative IVIg<br />product or when there has been a long interval since the previous infusion, should be<br />monitored during the first infusion and for the first hour after the first infusion, in order<br />to detect potential adverse signs. All other patients should be observed for at least 20<br />minutes after administration.<br />In case of adverse reaction, either the rate of administration must be reduced or the infusion<br />stopped. The treatment required depends on the nature and severity of the adverse reaction.<br />In case of shock, standard medical treatment for shock should be implemented.</p><p>Higher doses may be associated with increased rates of adverse effects. Therefore, the lowest<br />effective dose should be sought in individual patients and careful monitoring routine is to<br />establish.<br />In all patients, IVIg administration requires adequate hydration prior to the initiation of the<br />infusion.<br />Hypersensitivity<br />True hypersensitivity reactions are rare. They can occur in patients with anti-IgA antibodies.<br />IVIg is not indicated in patients with selective IgA deficiency where the IgA deficiency is the<br />only abnormality of concern.<br />Rarely, human normal immunoglobulin can induce a fall in blood pressure with anaphylactoid<br />reaction, even in patients who had tolerated previous treatment with human normal<br />immunoglobulin.<br />Haemolytic anaemia<br />IVIg products can contain blood group antibodies (e.g. anti-A and anti-B) which may act as<br />haemolysins and induce in vivo coating of red blood cells (RBC) with immunoglobulin,<br />causing a positive direct antiglobulin reaction (Coombs` test) and, rarely, haemolysis.<br />Haemolytic anaemia can develop subsequent to IVIg therapy due to enhanced RBC<br />sequestration. The Privigen manufacturing process includes an immunoaffinity chromatography<br />(IAC) step that specifically reduces blood group A and B antibodies (isoagglutinins A and B). Clinical<br />data with Privigen manufactured with the IAC step is not available.<br />Isolated cases of haemolysis-related renal dysfunction/renal failure or disseminated<br />intravascular coagulation in some cases leading to death have occurred.<br />The following risk factors are associated with the development of haemolysis: high doses,<br />whether given as a single administration or divided over several days; blood group A, B and<br />AB (non-0 blood group) and underlying inflammatory state. As this event was commonly<br />reported in patients with blood group A, B or AB (non-0 blood group) receiving high doses<br />for non-PID indications, increased vigilance is recommended.<br />Haemolysis has rarely been reported in patients given replacement therapy for PID.<br />IVIg recipients should be monitored for clinical signs and symptoms of haemolysis. If signs<br />and/or symptoms of haemolysis develop during or after IVIg infusion, discontinuation of IVIg<br />treatment should be considered by the treating physician (see also section &ldquo;Undesirable<br />effects&rdquo;).</p><p>Aseptic meningitis syndrome (AMS)<br />Aseptic meningitis syndrome has been reported to occur in association with IVIg treatment.<br />Discontinuation of IVIg treatment has resulted in remission of AMS within several days<br />without sequelae. The syndrome usually begins within several hours to 2 days following IVIg<br />treatment. Cerebrospinal fluid studies are frequently positive with pleocytosis up to several<br />thousand cells per mm3 (predominantly from the granulocytic series) and elevated protein<br />levels up to several hundred mg/dl.<br />AMS may occur more frequently in association with high-dose (2 g/kg) IVIg treatment.</p><p>Thromboembolism<br />There is clinical evidence of an association between IVIg administration and thromboembolic<br />events such as myocardial infarction, cerebral vascular accident (including stroke), pulmonary<br />embolism and deep vein thromboses which is assumed to be related to a relative increase in<br />blood viscosity through the high influx of immunoglobulins in at-risk patients. Therefore<br />caution should be exercised in prescribing and infusing IVIg in obese patients and in patients<br />with pre-existing risk factors for thrombotic events (such as advanced age, hypertension,<br />diabetes mellitus, a history of vascular disease or thrombotic episodes, acquired or inherited<br />thrombophilic disorders, prolonged periods of immobilisation, severe hypovolaemia, diseases<br />which increase blood viscosity).</p><p>In patients at risk for thromboembolic reactions, IVIg products should be administered at the<br />minimum rate of infusion and minimum dose practicable.<br />Acute renal failure<br />Cases of acute renal failure have been reported in patients receiving IVIg therapy. In most<br />cases risk factors have been identified e.g. pre-existing renal insufficiency, diabetes mellitus,<br />hypovolaemia, overweight, concomitant nephrotoxic medicinal products or age over 65.<br />In case of renal impairment, IVIg discontinuation should be considered.<br />While these reports of renal dysfunction and acute renal failure have been associated with the<br />use of many of the licensed IVIg products containing various excipients such as sucrose,<br />glucose and maltose those containing sucrose as a stabiliser accounted for a disproportionate<br />share of the total number. In patients at risk, the use of IVIg products that do not contain<br />sucrose should therefore be considered. Privigen does not contain sucrose, maltose or glucose.<br />In patients at risk of acute renal failure, IVIg products should be administered at the minimum<br />rate of infusion and minimum dose practicable.<br />Transfusion-related acute lung injury (TRALI)<br />Noncardiogenic pulmonary edema may very rarely occur following treatment with IVIg<br />products, including Privigen. TRALI is characterized by severe respiratory distress,<br />pulmonary edema, hypoxemia, normal left ventricular function, and fever. Symptoms<br />typically appear within 1 to 6 hours following treatment.<br />Monitor patients for pulmonary adverse reactions. TRALI may be managed using oxygen<br />therapy with adequate ventilatory support.</p><p>Pathogen safety<br />Privigen is made from human plasma. Because this product is made from human blood, it<br />may carry a risk of transmitting infectious agents. e.g., viruses, and theoretically, the<br />Creutzfeldt-Jakob disease (CJD) and Variant Creutzfeldt-Jakob disease (vCJD) agent. There<br />is also the possibility that unknown infectious agents may be present in such products.<br />Standard measures to prevent infections resulting from the use of medicinal products prepared<br />from human blood or plasma include selection of donors, screening of individual donations<br />and plasma pools for specific markers of infection and the inclusion of effective<br />manufacturing steps for the inactivation/removal of viruses (see also section<br />&ldquo;Properties/Effects&rdquo;). Despite this, when medicinal products prepared from human blood or<br />plasma are administered, the possibility of transmitting infective agents cannot be totally<br />excluded. This also applies to unknown or emerging viruses and other pathogens.<br />The measures taken are considered effective for enveloped viruses such as human<br />immunodeficiency (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV), and for the<br />non-enveloped viruses such as hepatitis A (HAV) and parvovirus B19.<br />There is reassuring clinical experience regarding the lack of hepatitis A or parvovirus B19<br />transmission with immunoglobulins, and it is also assumed that the antibody content makes an<br />important contribution to the viral safety.<br />It is recommended that every time Privigen is administered to a patient, the name and batch<br />number of the product are recorded in order to maintain a link between the patient and the<br />batch of the product.<br />Sodium content<br />Privigen is essentially sodium-free (Privigen has a low sodium content of &le; 1 mmol/l).<br />Paediatric population<br />Although limited data is available, it is expected that the same warnings, precautions and risk<br />factors apply to the paediatric population.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Live attenuated virus vaccines<br />After treatment with immunoglobulins, the efficacy of live attenuated vaccines, such as<br />measles, mumps, rubella and chickenpox vaccines, may be impaired for a period of at least 6<br />weeks and up to 3 months. An interval of 3 months should elapse before vaccination with live<br />attenuated vaccines. In the case of measles vaccinations, the decrease in efficacy may persist<br />for up to a year. Patients given measles vaccine should therefore have their antibody status<br />checked.<br />Paediatric population<br />Although limited data is available, it is expected that the same interactions may occur in the<br />paediatric population.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy Category C.<br />There are no adequate and well-controlled studies in pregnant women. Privigen should be<br />used during pregnancy only if the potential benefit justifies the potential risk to the fetus.<br />Animal reproduction studies have not been conducted with Privigen.<br />Clinical experience with immunoglobulins suggests that no harmful effects on the course of<br />pregnancy, or on the foetus and the neonate are to be expected.<br />Privigen should be given to a pregnant woman only if clearly needed.<br />Breast-feeding<br />Immunoglobulins are excreted into the milk and may contribute to protecting the neonate<br />from pathogens which have a mucosal portal of entry.<br />Fertility<br />Clinical experience with immunoglobulins suggests that no harmful effects on fertility are to<br />be expected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The ability to drive and operate machines may be impaired by some adverse reactions<br />associated with Privigen. Patients who experience adverse reactions during treatment should<br />wait for these to resolve before driving or operating machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions such as chills, headache, dizziness, fever, vomiting, allergic reactions,<br />nausea, arthralgia, low blood pressure, and moderate back pain may occur occasionally in<br />connection with intravenous administration of human immunoglobulin including Privigen.<br />Rarely human immunoglobulin including Privigen may cause hypersensitivity reactions with<br />a sudden fall in blood pressure and, in isolated cases, anaphylactic shock, even when the<br />patient has shown no hypersensitivity to previous administration.<br />Cases of reversible aseptic meningitis and rare cases of transient cutaneous reactions have<br />been observed with human normal immunoglobulin including Privigen.<br />Reversible haemolytic reactions have been observed in patients, especially those with blood<br />groups A, B, and AB (non-0-blood groups) in immunomodulatory treatment. Rarely,<br />haemolytic anaemia requiring transfusion may develop after high dose IVIg treatment<br />including Privigen (see section &ldquo;Warnings and precautions&rdquo;).<br />Increase in serum creatinine levels and/or acute renal failure have been observed.<br />Very rarely: transfusion related acute lung injury and thromboembolic reactions such as<br />myocardial infarction, stroke, pulmonary embolism, and deep vein thrombosis have occurred.</p><p>Tabulated list of adverse reactions<br />Six clinical studies were performed with Privigen, which included patients with PID, ITP and<br />CIDP patients respectively. In the PID pivotal study, 80 patients were enrolled and treated<br />with Privigen. Of these, 72 completed the 12 months of treatment. In the PID extension study,<br />55 patients were enrolled and treated with Privigen. The two ITP studies were performed with<br />57 patients each. The two CIDP studies were performed with 28 and 207 patients,<br />respectively.<br />Most adverse drug reactions (ADRs) observed in the six clinical studies were mild to<br />moderate in nature.<br />The following table shows an overview of the ADRs in the six studies, categorized according<br />to MedDRA System Organ Class (SOC and Preferred Term Level (PT)) and frequency.<br />Frequencies per infusion were evaluated according to the following conventions: Very<br />common (&ge; 1/10), Common (&ge; 1/100 to &lt; 1/10), Uncommon (&ge; 1/1,000 to &lt; 1/100). For<br />spontaneous post-marketing ADRs, the reporting frequency is categorized as unknown.<br />Within each frequency grouping, undesirable effects are presented in order of decreasing<br />frequency.</p><table border="1" cellspacing="1" cellpadding="1" style="width:679px"><tbody><tr><td style="text-align:center; width:143px">MedDRA System<br />Organ Class</td><td style="text-align:center; width:170px">Adverse Reaction<br />MedDRA Preferred Term</td><td style="text-align:center; width:363px">ADR frequency<br />category</td></tr><tr><td style="text-align:center; width:143px">Infections and<br />infestations</td><td style="text-align:center; width:170px">Aseptic meningitis</td><td style="text-align:center; width:363px">Uncommon</td></tr><tr><td style="text-align:center; width:143px">Blood and lymphatic<br />system disorders</td><td style="width:170px"><p style="text-align:center">1- Anaemia, haemolysis (including<br />haemolytic anaemia), leukopenia</p><p style="text-align:center">2 -&nbsp;Anisocytosis (including microcytosis),<br />thrombocytosis</p></td><td style="width:363px"><p style="text-align:center">1- Common</p><p style="text-align:center">&nbsp;</p><p style="text-align:center">&nbsp;</p><p style="text-align:center">2- Uncommon</p></td></tr><tr><td style="text-align:center; width:143px">Immune system<br />disorders</td><td style="width:170px"><p style="text-align:center">1- Hypersensitivity</p><p style="text-align:center">2-&nbsp;Anaphylactic shock</p></td><td style="width:363px"><p style="text-align:center">1-Common</p><p style="text-align:center">2-Unknown</p></td></tr><tr><td style="text-align:center; width:143px">Nervous system<br />disorders</td><td style="width:170px"><p style="text-align:center">1-&nbsp;Headaches (including sinus headache,<br />migraine, head discomfort, tension<br />headache)</p><p style="text-align:center">2-Dizziness (including vertigo)</p><p style="text-align:center">3-Somnolence, tremor</p></td><td style="width:363px"><p style="text-align:center">1- Very Common</p><p style="text-align:center">&nbsp;</p><p style="text-align:center">&nbsp;</p><p style="text-align:center">2- Common</p><p style="text-align:center">&nbsp;</p><p style="text-align:center">3-Uncommon</p></td></tr><tr><td style="text-align:center; width:143px">Cardiac disorders</td><td style="text-align:center; width:170px">Palpitations, tachycardia</td><td style="text-align:center; width:363px">Uncommon</td></tr><tr><td style="text-align:center; width:143px">Vascular disorders</td><td style="width:170px"><p style="text-align:center">1-Hypertension, flushing (including hot flush,<br />hyperaemia), hypotension</p><p style="text-align:center">2-Thromboembolic events, vasculitis<br />(including peripheral vascular disorder)</p><p style="text-align:center">3-Transfusion related acute lung injury</p></td><td style="width:363px"><p style="text-align:center">1- Common</p><p style="text-align:center">&nbsp;</p><p style="text-align:center">2- UnCommon</p><p style="text-align:center">&nbsp;</p><p style="text-align:center">3-Uncommon</p></td></tr><tr><td style="text-align:center; width:143px">Respiratory, thoracic<br />and mediastinal<br />disorders</td><td style="text-align:center; width:170px">Dyspnoea (including chest pain, chest<br />discomfort, painful respiration)</td><td style="text-align:center; width:363px">Common</td></tr><tr><td style="text-align:center; width:143px">Gastrointestinal<br />disorders</td><td style="width:170px"><p style="text-align:center">1-Nausea</p><p style="text-align:center">2-Vomiting, diarrhoea, abdominal pain</p></td><td style="width:363px"><p style="text-align:center">1- Very common</p><p style="text-align:center">2-Common</p></td></tr><tr><td style="text-align:center; width:143px">Hepatobiliary disorders</td><td style="text-align:center; width:170px">Hyperbilirubinaemia</td><td style="text-align:center; width:363px">Common</td></tr><tr><td style="text-align:center; width:143px">Skin and subcutaneous<br />tissue disorders</td><td style="text-align:center; width:170px">Skin disorder (including rash, pruritus,<br />urticaria, maculo-papular rash, erythema,<br />skin exfoliation)</td><td style="text-align:center; width:363px">Common</td></tr><tr><td style="text-align:center; width:143px">Musculoskeletal and<br />connective tissue<br />disorders</td><td style="text-align:center; width:170px">Myalgia (including muscle spasms,<br />musculoskeletal stiffness, muscuskeletal<br />pain)</td><td style="text-align:center; width:363px">Common</td></tr><tr><td style="text-align:center; width:143px">Renal and urinary<br />disorders</td><td style="width:170px"><p style="text-align:center">1-Proteinuria, increased blood creatinine</p><p style="text-align:center">2-Acute renal failure</p></td><td style="width:363px"><p style="text-align:center">1-Uncommon</p><p style="text-align:center">2-Unknown</p></td></tr><tr><td style="text-align:center; width:143px">General disorders and<br />administration site<br />conditions</td><td style="width:170px"><p style="text-align:center">1-Pain (including back pain, pain in<br />extremity, arthralgia, neck pain, facial<br />pain), pyrexia (including chills), influenza<br />like illness (including nasopharyngitis,<br />pharyngolaryngeal pain, oropharyngeal<br />blistering, throat tightness)</p><p style="text-align:center">2-Fatigue, asthenia (including muscular<br />weakness)</p><p style="text-align:center">3-injection site pain</p></td><td style="width:363px"><p style="text-align:center">1- Very Common</p><p style="text-align:center">&nbsp;</p><p style="text-align:center">&nbsp;</p><p style="text-align:center">2- Common</p><p style="text-align:center">&nbsp;</p><p style="text-align:center">3-Uncommon</p></td></tr><tr><td style="text-align:center; width:143px">Investigations</td><td style="text-align:center; width:170px">Decreased haemoglobin (including<br />decreased red blood cell count, decreased<br />haematocrit), Coombs` (direct) test<br />positive, increased alanine<br />aminotransferase, increased aspartate<br />aminotransferase, increased blood lactate<br />dehydrogenase</td><td style="text-align:center; width:363px">Common</td></tr></tbody></table><p>For safety with respect to transmissible agents and additional details on risk factors, see<br />section &ldquo;Warnings and precautions&rdquo;.<br />Paediatric Population<br />In Privigen clinical studies with paediatric patients, the frequency, nature and severity of<br />adverse reactions did not differ between children and adults. In postmarketing reports it is<br />observed that the proportion of haemolysis cases to all case reports occurring in children is<br />slightly higher than in adults. Please refer to section &rdquo;Warnings and precautions&rdquo; for details<br />on risk factors and monitoring recommendations.<br />Reporting of suspected adverse reactions<br />Reporting suspected adverse reactions after authorisation of the medicinal product is<br />important. It allows continued monitoring of the benefit/risk balance of the medicinal product.<br />Healthcare professionals are asked to report any suspected adverse reactions.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose can lead to fluid volume overload and hyperviscosity, particularly in patients at<br />risk, including elderly patients or patients with cardiac or renal impairment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mechanism of Action/Pharmacodynamics<br />Privigen is prepared from plasma from 1000 or more human donors. The manufacturing<br />process for Privigen includes the following steps: ethanol precipitation of the IgG plasma<br />fraction, followed by octanoic acid fractionation and incubation at pH 4. Subsequent<br />purification steps comprise depth filtration, chromatography, immunoaffinity chromatography to<br />specifically reduce blood group A and B antibodies (isoagglutinins A and B) and a filtration step<br />that can remove particles to a size of 20 nm.<br />Privigen contains mainly IgG that are present in the normal human population and that show a broad<br />spectrum of functionally intact antibodies against infectious agents. In the replacement therapy<br />adequate doses of Privigen may restore abnormally low IgG levels to the normal range.<br />The IgG subclass distribution in Privigen corresponds roughly to that of native human plasma. Both<br />the Fc and the Fab functions of the IgG molecules are preserved. The ability of the Fab parts<br />to bind antigens was demonstrated with biochemical and biological methods. The Fc function<br />was tested with complement activation and with Fc receptor-mediated leukocyte activation.<br />The inhibition of immune complex-induced complement activation (&ldquo;scavenging&rdquo;, an antiinflammatory<br />function of IVIgs) is preserved in Privigen. Privigen does not lead to nonspecific<br />activation of the complement system or of prekallikrein.<br />The mechanism of action in indications other than replacement therapy is not fully elucidated,<br />but includes immunomodulatory effects.</p><p>Clinical Efficacy<br />The safety and efficacy of Privigen was investigated in 6 prospective, open, single-arm,<br />multicentre studies carried out in Europe (ITP, PID and CIDP studies) and in the USA (PID<br />study). Further data on safety and efficacy were collected in a prospective, open, single-arm,<br />multicentre extension study with PID patients performed in the USA.<br />PID<br />In the pivotal study, 80 patients between 3 and 69 years of age with PID were given a<br />Privigen infusion at a median dose of 200-888 mg/kg bw every 3 to 4 weeks for at most 1<br />year. With this treatment, constant IgG trough levels were achieved over the whole of the<br />treatment period, the mean concentrations being 8.84 g/l to 10.27 g/l. The incidence of acute,<br />severe bacterial infections (aSBI) was 0.08 per patient per year (the upper 97.5% confidence<br />limit was 0.182).<br />As in the pivotal study, Privigen dosages were administered in the PID extension study to a<br />total of 55 patients (of which 45 had already been treated in the pivotal study and 10 were<br />newly recruited patients). The results of the pivotal study were confirmed for the average IgG<br />trough levels (9.31 g/l to 11.15 g/l) and the rate of aSBI (0.018 per patient per year with an<br />upper 97.5 % confidence interval of 0.098).<br />ITP<br />57 patients aged between 15 and 69 years with chronic ITP took part in the ITP study. Their<br />platelet count at the start was 20 x 109/l. After administration of Privigen at a dose 1 g/kg bw</p><p>on two consecutive days, the platelet count rose to at least 50 x 109/l within 7 days of the first<br />infusion in 80.7% of the patients. In 43% of the patients, this increase occurred after just one<br />day, before the second infusion. The mean time until this platelet count was reached was 2.5<br />days. In patients who responded to the treatment, the platelet count remained &ge;50 x 109/l for a<br />mean period of 15.4 days.<br />In the second ITP study on patients aged between 18 and 65 years, in 42 subjects (74%) the<br />platelet count increased at least once to &ge;50 &times; 109/l within 6 days after the first infusion,<br />which was well within the expected range and similar to response rates were reported for<br />other IVIGs in this indication (70%). A second dose in subjects with platelet counts<br />&ge;50 &times; 109/l after the first dose provided a relevant additional benefit in terms of higher and<br />longer-lasting increases in platelet counts compared to a single dose. In subjects with platelet<br />counts &lt;50 &times; 109/l on day 3 receiving a mandatory second infusion, the lowest median platelet<br />count (8.0 &times; 109/l) was observed already at the baseline. In this group, only 30% of subjects<br />were observed with platelet response after the mandatory second dose. Consequently, it was<br />more difficult to increase platelet counts with one infusion in these subjects.</p><p>CIDP<br />In the first CIDP study, a prospective multicenter open label trial PRIMA (Privigen impact on<br />mobility and autonomy study), 28 patients with CIDP (13 subjects with and 15 without IVIg<br />pre-treatment) were treated with a loading dose of 2 g/kg bw given over 2-5 days followed by<br />6 maintenance doses of 1 g/kg bw given over 1-2 days every 3 weeks. Previously treated<br />patients were withdrawn from IVIg before treatment with Privigen until the deterioration of<br />clinical symptoms was confirmed on the basis of the INCAT scale (Inflammatory Neuropathy<br />Cause and Treatment). On the adjusted 10 point INCAT scale a clinically meaningful<br />improvement of at least 1-point from baseline to treatment week 25 was observed in 17 / 28<br />patients (60.7%, 95% confidence interval 42.41, 76.4). Nine patients responded already after<br />receiving the initial induction dose to the treatment at week 4 and 16 by week 10.<br />In a second clinical study, a prospective, multicenter randomized, placebo-controlled PATH<br />[Polyneuropathy and Treatment with Hizentra] study, 207 subjects with CIDP were treated with<br />Privigen in the prerandomization phase of the study. Subjects all with IVIg pretreatment of at least<br />8 weeks and an IVIg-dependence confirmed by clinically evident deterioration during an IVIg<br />withdrawal phase of up to 12 weeks, received a Privigen loading dose of 2 g/kg bw followed by up to<br />4 Privigen maintenance doses of 1 g/kg bw every 3 weeks for up to 13 weeks.<br />Following clinical deterioration during IVIg withdrawal, clinical improvement of CIDP was primarily<br />defined by a decrease of &ge; 1 point at the adjusted INCAT score. Additional measures of CIDP<br />improvement were an R-ODS increase of &ge; 4 points, a mean grip strength increase of &ge; 8 kPa, or an<br />MRC sum score increase of &ge; 3 points. Overall, 91 % of subjects (188 patients) showed improvement<br />in at least one of the criteria above by week 13.<br />By adjusted INCAT score, the responder rate by week 13 was 72.9 % (151 / 207 patients), with<br />149 patients responding already by week 10. A total of 43 of the 207 patients achieved a better CIDP<br />status as assessed by the adjusted INCAT score compared to their CIDP status at study entry.<br />The comparability of the response rates and mean adjusted INCAT scores for the IVIg pretreated<br />subjects in both PRIMA and PATH study are shown in the Figure 1 below.</p><p>Figure 1. Percentage of Responders (Adjusted INCAT Score)</p><p>IVIg: intravenous immunoglobulin; Ref Visit: reference visit<br />The mean improvement at the end of the treatment period compared to reference visit was 1.4 points<br />in the PRIMA (1.8 points in IVIg pretreated subjects) and 1.2 points in PATH study.<br />In PRIMA, the percentage of responders in the overall Medical Research Council (MRC) score<br />(defined as an increase by &ge; 3 points) was 85 % (87 % in the IVIg-untreated and 82 % in IVIgpretreated)<br />and 57 % in PATH. The overall median time to first MRC sum score response in PRIMA<br />was 6 weeks (6 weeks in the IVIg-untreated and 3 weeks in the IVIg-pretreated) and 9.3 weeks in<br />PATH. MRC sum score in PRIMA improved by 6.9 points (7.7 points for IVIg-untreated and<br />6.1 points for IVIg-pretreated) and by 3.6 points in PATH.<br />The grip strength of the dominant hand improved by 14.1 kPa (17.0 kPa in IVIg-untreated and<br />10.8 kPa in IVIg pretreated subjects) in the PRIMA study, while in PATH the grip strength of the<br />dominant hand improved by 12.2 kPa. For the non-dominant hand similar results were observed in<br />both studies, PRIMA and PATH.<br />The efficacy and safety profile in the PRIMA and the PATH study in CIDP patients were overall<br />comparable.<br />Paediatric population<br />No differences were seen in the pharmacodynamic properties between adult and paediatric<br />study patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Privigen is immediately and completely bioavailable in the recipient&rsquo;s circulation after<br />intravenous administration. It is distributed relatively quickly between plasma and<br />extravascular fluid. Equilibrium between the intravascular and extravascular compartments is<br />reached after approximately 3 to 5 days.</p><p>IgG and IgG complexes are broken down in the cells of the reticuloendothelial system. The half-life<br />may vary from patient to patient.<br />The pharmacokinetic parameters for Privigen were determined in both clinical studies in<br />patients with primary immunodeficiency syndrome (see section &ldquo;Properties/Effects&rdquo;). 25<br />patients (aged 13 to 69 years) in the pivotal study and 13 patients (aged 9 to 59 years) in an<br />extension of this study participated in the pharmacokinetic (PK) assessment (see table below).</p><p>Pharmacokinetic parameters of Privigen in patients with primary immunodeficiency<br />syndrome</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td style="width:120px">Parameter</td><td style="width:173px">Pivotal study (N=25)<br />Median (range)</td><td style="width:205px">Extension study (N=13)<br />Median (range)</td></tr><tr><td style="width:120px">Cmax (peak level) in g/l</td><td style="width:173px">23.4 (10.4-34.6)</td><td style="width:205px">26.3 (20.9-32.9)</td></tr><tr><td style="width:120px">Cmin (trough level) in g/l</td><td style="width:173px">10.2 (5.8-14.7)</td><td style="width:205px">9.75 (5.72-18.01)</td></tr><tr><td style="width:120px">t&frac12; (half-life) in days</td><td style="width:173px">36.6 (20.6-96.6)</td><td style="width:205px">31.1 (14.6-43.6)</td></tr></tbody></table><p>Cmax, maximum serum concentration; Cmin, trough (minimum level) serum concentration; t&frac12;, elimination half-life.</p><p>In the pivotal study the median half-life of Privigen in primary immunodeficiency patients<br />was 36.6 days and 31.1 days in the extension of this study.<br />Paediatric population<br />No differences were seen in the pharmacokinetic parameters between adult and paediatric<br />study patients with PID. There are no data on pharmacokinetic properties in paediatric<br />patients with CIDP.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The safety of Privigen has been investigated in several preclinical studies with particular<br />reference to the excipient L-proline. L-proline is a physiological, non-essential amino acid.<br />Studies in rats given daily L-proline doses of 1450 mg/kg bw did not show any evidence of<br />teratogenicity or embryotoxicity. Genotoxicity studies of L-proline did not show any<br />pathological findings.<br />Some published studies pertaining to hyperprolinaemia have shown that long-term, high doses<br />of L-proline have effects on brain development in very young rats. However, in studies where<br />the dosing was designed to reflect the clinical indications for Privigen, no effects on brain<br />development were observed. Further safety-pharmacology studies of L-proline in adult and<br />juvenile rats did not reveal behavioural disorders.<br />Immunoglobulins are natural components of the human body. Data from animal testing of<br />acute and chronic toxicity and embryofoetal toxicity of immunoglobulins are inconclusive on<br />account of interactions between immunoglobulins from heterogeneous species and the<br />induction of antibodies to heterologous proteins. In local tolerability studies in rabbits in<br />which Privigen was administered intravenously, paravenously, intra-arterially, and<br />subcutaneously, the product was well tolerated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>L-proline, water for injections.<br />Privigen contains trace amounts of sodium (&le; 1 mmol/l).<br />Privigen contains no preservatives.<br />Privigen contains no carbohydrate stabiliser (e.g. sucrose, maltose).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Incompatibilities<br />This medicine must not be mixed with other medicinal products nor with physiological saline.<br />However, dilution with 5% glucose solution is permitted.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Privigen is intended for single use. Because the solution contains no preservative, Privigen
should be used / infused immediately once opened.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store at 2 - 25 &deg;C. Do not freeze. Do not use if Privigen has been frozen. Do not shake.<br />Keep out of the sight and reach of children.<br />Keep the vial in the outer carton in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>NA</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Privigen is a ready-to-use solution. The product should be at room or body temperature before<br />use. A vented infusion line with integrated filter should be used for the administration of<br />Privigen. Always pierce the stopper at its centre, within the marked area.<br />If dilution is desired, 5% glucose solution should be used. For obtaining an immunoglobulin<br />solution of 50 mg/ml (5%), Privigen 100 mg/ml (10%) should be diluted with an equal<br />volume of the 5% glucose solution. Aseptic technique must be strictly observed during the<br />dilution of Privigen.<br />Privigen must not be mixed with physiological saline. However, after-rinsing of the infusion<br />tubes with physiological saline is permitted.<br />The solution must be clear or slightly opalescent. Do not use solutions that are cloudy or have<br />particulate matter.<br />Any unused product and waste material should be disposed of in accordance with local<br />requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufactured by:
CSL Behring AG
Bern, Switzerland
Marketing Authorisation Number
2.5g: 4-470-12
5g: 3-470-12
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                12/2018
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>